You’re using a public version of DrugPatentWatch with 1 free search available | Register to unlock more free searches. CREATE FREE ACCOUNT

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Express Scripts

Last Updated: December 9, 2023

Peramivir - Generic Drug Details

✉ Email this page to a colleague

« Back to Dashboard

What are the generic sources for peramivir and what is the scope of patent protection?

Peramivir is the generic ingredient in one branded drug marketed by Biocryst and is included in one NDA. There are three patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Peramivir has seventy patent family members in twenty-eight countries.

There is one drug master file entry for peramivir. One supplier is listed for this compound.

Summary for peramivir
International Patents:70
US Patents:3
Drug Master File Entries: 1
Finished Product Suppliers / Packagers: 1
Raw Ingredient (Bulk) Api Vendors: 146
Clinical Trials: 16
Patent Applications: 2,587
What excipients (inactive ingredients) are in peramivir?peramivir excipients list
DailyMed Link:peramivir at DailyMed
DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for peramivir
Generic Entry Date for peramivir*:
Constraining patent/regulatory exclusivity:

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for peramivir

Identify potential brand extensions & 505(b)(2) entrants

University of OxfordPhase 2
Hoffmann-La RochePhase 3
Johns Hopkins UniversityPhase 4

See all peramivir clinical trials

US Patents and Regulatory Information for peramivir

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Biocryst RAPIVAB peramivir SOLUTION;INTRAVENOUS 206426-001 Dec 19, 2014 RX Yes Yes ⤷  Try a Trial ⤷  Try a Trial Y ⤷  Try a Trial
Biocryst RAPIVAB peramivir SOLUTION;INTRAVENOUS 206426-001 Dec 19, 2014 RX Yes Yes ⤷  Try a Trial ⤷  Try a Trial ⤷  Try a Trial
Biocryst RAPIVAB peramivir SOLUTION;INTRAVENOUS 206426-001 Dec 19, 2014 RX Yes Yes ⤷  Try a Trial ⤷  Try a Trial ⤷  Try a Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

EU/EMA Drug Approvals for peramivir

Company Drugname Inn Product Number / Indication Status Generic Biosimilar Orphan Marketing Authorisation Marketing Refusal
Biocryst Alpivab peramivir EMEA/H/C/004299
Alpivab is indicated for the treatment of uncomplicated influenza in adults and children from the age of 2 years.
Withdrawn no no no 2018-04-13
>Company >Drugname >Inn >Product Number / Indication >Status >Generic >Biosimilar >Orphan >Marketing Authorisation >Marketing Refusal

International Patents for peramivir

Country Patent Number Title Estimated Expiration
Denmark 1040094 ⤷  Try a Trial
Poland 196674 ⤷  Try a Trial
Austria 425955 ⤷  Try a Trial
South Korea 20160129105 정맥내 항바이러스 치료 (INTRAVENOUS ANTIVIRAL TREATMENTS) ⤷  Try a Trial
Japan 5118502 ⤷  Try a Trial
South Korea 20210076189 정맥내 항바이러스 치료 (INTRAVENOUS ANTIVIRAL TREATMENTS) ⤷  Try a Trial
Japan 2001527058 ⤷  Try a Trial
>Country >Patent Number >Title >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.